血管内皮生长因子受体与肝细胞癌侵袭转移的关系

李存娣; 曹伟娅; 王健

doi:10.3969/j.issn.1001-5256.2019.07.042

血管内皮生长因子受体与肝细胞癌侵袭转移的关系

DOI: 10.3969/j.issn.1001-5256.2019.07.042

安徽理工大学医学院病原生物学教研室

基金项目:

安徽省教育厅重大自然科学研究项目(KJ2016SD20)；中国煤炭工业协会科研项目(MTKJ 2015-333)；安徽省自然科学基金(1308085MH148)；安徽省2015年高等教育振兴计划项目重大教学改革研究项目(2015zdjy068)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 920
- HTML全文浏览量: 11
- PDF下载量: 248
- 被引次数: 0
出版历程
- 收稿日期: 2019-01-02
- 出版日期: 2019-07-20

Expression of vascular endothelial growth factor receptors and invasion and metastasis of hepatocellular carcinoma

Department of Etiology and Immunology, Medical College of Anhui University of Science and Technology

Research funding:

摘要

摘要: 血管内皮生长因子受体（VEGFR）含3种受体酪氨酸激酶（RTK）超家族成员和2种非RTK超家族成员,其与配体以非一一对应形式相互结合,通过细胞表面受体内化作用介导Raf1→MAP2K1/2→ERK1/2等多条信号传导通路,引起肝癌细胞增殖和血管、淋巴管生成。VEGFR在肝癌患者局部癌灶高表达,是介导肝细胞癌恶性增生、侵袭转移的关键因素,与患者无进展生存期呈负相关。基质金属蛋白酶-9、热休克蛋白90β可上调VEGFR促进肝癌细胞增殖转移,而miR-203a、miR-378a、miR-199a-3p等可下调VEGFR表达抑制肝癌细胞浸润。基于VEGFR靶向药物治疗可诱导肝癌细胞凋亡,阻断肿瘤血管新生,延缓患者病情进展。
- 受体,血管内皮生长因子 /
- 癌,肝细胞 /
- 肿瘤形成过程
Abstract: Vascular endothelial growth factor receptors ( VEGFRs) consist of three receptor tyrosine kinase ( RTK) superfamily members and two non-RTK superfamily members and bind to the ligand in a non-one-to-one way. VEGFRs mediate various signaling pathways such as Raf1→MAP2 K1/2→ERK1/2 through cell surface receptor internalization and thus promote the proliferation of hepatocellular carcinoma cells, angiogenesis, and lymphangiogenesis. VEGFRs can be highly expressed in local cancerous lesions of liver cancer patients, which is a key factor mediating malignant proliferation, invasion, and metastasis of hepatocellular carcinoma, and the expression of VEGFRs is negatively correlated with progression-free survival. Matrix metalloproteinase-9 and heat shock protein 90β can upregulate VEGFRs to promote the proliferation and metastasis of hepatoma cells, while miR-203 a, miR-378 a, and miR-199 a-3 p can downregulate VEGFR expression and inhibit hepatoma cell infiltration. Targeted drug therapy based on VEGFR can induce the apoptosis of hepatoma cells, block tumor angiogenesis, and delay disease progression.
- receptors, vascular endothelial growth factor /
- carcinoma, hepatocellular /
- neoplastic processes

HTML全文

参考文献(26)

[1]PARK SA, JEONG MS, HA KT, et al.Structure and function of vascular endothelial growth factor and its receptor system[J].BMB Rep, 2018, 51 (2) :73-78.

[2]FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2018, 391 (10127) :1301-1314.

[3]SHIBUYA M, YAMAGUCHI S, YAMANE A, et al.Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family[J].Oncogene, 1990, 5 (4) :519-524.

[4]de VRIES C, ESCOBEDO JA, HOUCK K, et al.The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor[J].Science, 1992, 255 (5047) :989-991.

[5]ZHANG J, JIANG X, JIANG Y, et al.Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors asanticancer drugs[J].Eur J Med Chem, 2016, 108:495-504.

[6]ROSKOSKI R Jr.Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas[J].Pharmacol Res, 2017, 120:116-132.

[7]LEE SY, OH SC.Changing strategies for target therapy in gastric cancer[J].World J Gastroenterol, 2016, 22 (3) :1179-1189.

[8]HU YL, SUN DW, LUO FX, et al.Influencing factors for microvascular invasion in patients with single hepatocellular carcinoma and their prognosis[J].J Clin Hepatol, 2018, 34 (9) :1911-1916. (in Chinese) 胡月雷, 孙大伟, 骆飞翔, 等.单发肝细胞癌发生微血管侵犯的影响因素及预后分析[J].临床肝胆病杂志, 2018, 34 (9) :1911-1916.

[9]EICHMANN A, SIMONS M.VEGF signaling inside vascular endothelial cells and beyond[J].Curr Opin Cell Biol, 2012, 24 (2) :188-193.

[10]TAKAHASHI T, YAMAGUCHI S, CHIDA K, et al.A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells[J].EMBO J, 2001, 20 (11) :2768-2778.

[11]PENG S, WANG Y, PENG H, et al.Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma[J].Hepatology, 2014, 60 (4) :1264-1277.

[12]CHEN B, LIU J, WANG X, et al.Co-expression of PDGF-Band VEGFR-3 strongly correlates with poor prognosis in hepatocellular carcinoma patients after hepatectomy[J].Clin Res Hepatol Gastroenterol, 2018, 42 (2) :126-133.

[13]CAI H, SAIYIN H, LIU X, et al.Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma[J].Mol Oncol, 2018, 12 (12) :2042-2054.

[14]LI T, ZHU Y, HAN L, et al.VEGFR-1 activation-induced MMP-9-dependent invasion in hepatocellular carcinoma[J].Future Oncol, 2015, 11 (23) :3143-3157.

[15]MENG J, LIU Y, HAN J, et al.Hsp90βpromoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma[J].Mol Cancer, 2017, 16 (1) :72.

[16]GHOSH A, DASGUPTA D, GHOSH A, et al.MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2[J].Cell Death Dis, 2017, 8 (3) :e2706.

[17]WANG L, TONG D, GUO Q, et al.HOXD3 targeted by miR-203a suppresses cell metastasis and angiogenesis through VEGFR in human hepatocellular carcinoma cells[J].Sci Rep, 2018, 8 (1) :2431.

[18]FU H, ZHANG J, PAN T, et al.miR-378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβand c-Raf[J].Mol Med Rep, 2018, 17 (3) :4581-4588.

[19]SPALLANZANI A, ORSI G, ANDRIKOU K, et al.Lenvatinib as a therapy for unresectable hepatocellular carcinoma[J].Expert Rev Anticancer Ther, 2018, 18 (11) :1069-1076.

[20]NEGRI FV, DAL BELLO B, PORTA C, et al.Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment[J].Liver Int, 2015, 35 (8) :2001-2008.

[21]KUDO M, FINN RS, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J].Lancet, 2018, 391 (10126) :1163-1173.

[22]KELLEY RK, VERSLYPE C, COHN AL, et al.Cabozantinib in hepatocellular carcinoma:Results of a phase 2 placebo-controlled randomized discontinuation study[J].Ann Oncol, 2017, 28 (3) :528-534.

[23]SAMAD NA, ABDUL AB, RAHMAN HS, et al.Zerumbone suppresses angiogenesis in HepG2 cells through inhibition of matrix metalloproteinase-9, vascular endothelial growth factor, and vascular endothelial growth factor receptor expressions[J].Pharmacogn Mag, 2018, 13 (4) :s731-s736.

[24]LEE WS, PYUN BJ, KIM SW, et al.TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis[J].MAbs, 2015, 7 (5) :957-968.

[25]WANG Y, YAN Z, HUANG Y, et al.Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma[J].Am J Cancer Res, 2017, 7 (3) :603-609.

[26]HUANG J, TANG Q, WANG C, et al.Molecularly targeted therapy of human hepatocellular carcinoma xenografts with radio-iodinated Anti-VEGFR2 murine-human chimeric Fab[J].Sci Rep, 2015, 5:10660.

施引文献

资源附件(0)

访问统计